See our latest webinar entitled “A new concept of amblyopia screening”.
Euvision, Ltd. is a corporate entity resplendent with an academic background, promoting diversity, ingenuity and innovation in the field of ophthalmology. Euvision’s mission is to conceptualize, develop and market medical technologies regarding the field of vision, promoting the care and well-being of human eyesight. Ideally, Euvison’s arsenal includes pristine medical equipment used to evaluate the risk of amblyopia, a common childhood disease responsible for the majority of vision loss among individuals under the age of forty.
Originally, the Euvision team evolved from areas of varied academic research and was forged from a group of young scientists devoted to beneficial research regarding binocular vision at the Medical School, University of Pécs. Euvision’s posture is two-fold, an eye for enriching its business acumen and improving eye examinations while pursuing academic achievements, including basic and clinical research, publishing in scientific journals and medical conferences.
In the dawning of 2021, Euvision will release an advancement regarding childhood vision screening, distinctly the EuvisionTab©, which is a mobile-based screening application designed for pediatric eye professionals, e.g., optometrists and ophthalmologists. EuvisionTab© is a compact, easy-to-use, cost-effective solution for mass screening regarding amblyopia and amblyogenic childhood eye conditions. EuvisionTab© integrates a dynamic/static stereo vision test and visual acuity testing module into a single medical device.
Product portfolio
Today, as a pediatric ophthalmologist or optometrist, you are dependent on a reliable stereovision test to detect binocular abnormalities, in particular, amblyopia and preambliopic conditions. Strikingly, the ultimate tool is now immediately accessible and operates on your mobile phone. All you need is an Android mobile device, red-green spectacles and the EuvisionTab app to perform the stereovision test.
EuvisionTab is a clinically tested, new generation medical device with a stereovision and visual acuity module integrated into a single tool. Dynamic, evidence-based and no monocular cues. You simply make a YES or NO decision regarding amblyopia and most amblyogenic conditions. You can use it for diagnosis, screening or follow-up procedures. Mass screening is now faster and easier than ever before since it stores all patient responses, communicates with the cloud and promptly calculates statistical probabilities. You can evaluate the risk immediately. You can choose between dynamic or static mode of random dot generation for the stereovision test with no need to measure the disparity threshold. Visual acuity testing is automatic and based on the adaptive best PEST algorithm, all you do is select and maintain the viewing distance. Dot size, disparity and line width are adjusted to the physical pixel size of your mobile device.
EuvisionTab can also be used in a long distance examination by using any of the video conference programs during a pandemic when social distancing is required.
Summary
- Versatile, random dot stereovision test
- Dynamic or static random dot generation
- No monocular cues
- Comprehensive effortless documentation
- Quick procedure, no disparity measurement
- Low dot density requires global stereopsis
- High sensitivity regarding amblyogenic conditions
- Self-emitting light
- Immediate unbiased risk evaluation
- Bedside or remote testing
- Cloud-based data storage and easy to share patient data
- Automatic or manual visual acuity testing
- Selectable optotypes: Snellen-E, Landolt-C
- Selectable log MAR or decimal scale